Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.91
BMRN's Cash to Debt is ranked lower than
81% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. BMRN: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
BMRN' s Cash to Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.23 Max: No Debt
Current: 0.91
Equity to Asset 0.64
BMRN's Equity to Asset is ranked lower than
55% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BMRN: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
BMRN' s Equity to Asset Range Over the Past 10 Years
Min: -0.4  Med: 0.60 Max: 0.95
Current: 0.64
-0.4
0.95
F-Score: 2
Z-Score: 6.34
M-Score: -1.64
WACC vs ROIC
14.52%
-6.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -12.42
BMRN's Operating margin (%) is ranked higher than
64% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. BMRN: -12.42 )
Ranked among companies with meaningful Operating margin (%) only.
BMRN' s Operating margin (%) Range Over the Past 10 Years
Min: -47.12  Med: -12.41 Max: 13.41
Current: -12.42
-47.12
13.41
Net-margin (%) -19.29
BMRN's Net-margin (%) is ranked higher than
61% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. BMRN: -19.29 )
Ranked among companies with meaningful Net-margin (%) only.
BMRN' s Net-margin (%) Range Over the Past 10 Years
Min: -33.88  Med: -15.42 Max: 54.7
Current: -19.29
-33.88
54.7
ROE (%) -7.81
BMRN's ROE (%) is ranked higher than
68% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. BMRN: -7.81 )
Ranked among companies with meaningful ROE (%) only.
BMRN' s ROE (%) Range Over the Past 10 Years
Min: -141.46  Med: -9.05 Max: 39.6
Current: -7.81
-141.46
39.6
ROA (%) -5.01
BMRN's ROA (%) is ranked higher than
71% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. BMRN: -5.01 )
Ranked among companies with meaningful ROA (%) only.
BMRN' s ROA (%) Range Over the Past 10 Years
Min: -9.25  Med: -4.87 Max: 18.88
Current: -5.01
-9.25
18.88
ROC (Joel Greenblatt) (%) -18.09
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. BMRN: -18.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMRN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -49.89  Med: -11.54 Max: 31.1
Current: -18.09
-49.89
31.1
Revenue Growth (3Y)(%) 10.10
BMRN's Revenue Growth (3Y)(%) is ranked higher than
59% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. BMRN: 10.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMRN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.2  Med: 11.20 Max: 97.3
Current: 10.1
-17.2
97.3
EBITDA Growth (3Y)(%) 4.00
BMRN's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. BMRN: 4.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BMRN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -77.9  Med: 14.30 Max: 52.8
Current: 4
-77.9
52.8
EPS Growth (3Y)(%) 4.10
BMRN's EPS Growth (3Y)(%) is ranked higher than
61% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. BMRN: 4.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMRN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.5  Med: 7.40 Max: 475.1
Current: 4.1
-75.5
475.1
» BMRN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-04-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

BMRN Guru Trades in Q2 2015

Kyle Bass 9,886 sh (New)
Jim Simons 123,671 sh (New)
Paul Tudor Jones 2,062 sh (New)
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 7,992,749 sh (-0.40%)
RS Investment Management 32,570 sh (-3.92%)
John Griffin 2,120,000 sh (-4.93%)
Frank Sands 11,627,607 sh (-5.74%)
» More
Q3 2015

BMRN Guru Trades in Q3 2015

Kyle Bass 129,501 sh (+1209.94%)
Paul Tudor Jones 6,208 sh (+201.07%)
Jim Simons 262,571 sh (+112.31%)
RS Investment Management 55,060 sh (+69.05%)
Frank Sands 11,395,866 sh (-1.99%)
Signature Select Canadian Fund 17,500 sh (-4.37%)
PRIMECAP Management 7,365,039 sh (-7.85%)
John Griffin 1,540,000 sh (-27.36%)
» More
Q4 2015

BMRN Guru Trades in Q4 2015

Louis Moore Bacon 122,000 sh (New)
RS Investment Management 99,240 sh (+80.24%)
Frank Sands 11,637,466 sh (+2.12%)
John Griffin 1,540,000 sh (unchged)
Kyle Bass Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 7,330,689 sh (-0.47%)
Jim Simons 193,571 sh (-26.28%)
» More
2016

BMRN Guru Trades in 2016

Spiros Segalas 781,714 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.71
BMRN's P/B is ranked lower than
72% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. BMRN: 5.71 )
Ranked among companies with meaningful P/B only.
BMRN' s P/B Range Over the Past 10 Years
Min: 3.68  Med: 6.81 Max: 27.45
Current: 5.71
3.68
27.45
P/S 15.29
BMRN's P/S is ranked lower than
58% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. BMRN: 15.29 )
Ranked among companies with meaningful P/S only.
BMRN' s P/S Range Over the Past 10 Years
Min: 3.39  Med: 15.29 Max: 34.36
Current: 15.29
3.39
34.36
EV-to-EBIT -100.20
BMRN's EV-to-EBIT is ranked lower than
99.99% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.70 vs. BMRN: -100.20 )
Ranked among companies with meaningful EV-to-EBIT only.
BMRN' s EV-to-EBIT Range Over the Past 10 Years
Min: -2242  Med: -57.20 Max: 305.6
Current: -100.2
-2242
305.6
EV-to-EBITDA -152.83
BMRN's EV-to-EBITDA is ranked lower than
99.99% of the 275 Companies
in the Global Biotechnology industry.

( Industry Median: 20.64 vs. BMRN: -152.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMRN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25504  Med: -72.65 Max: 1532.3
Current: -152.83
-25504
1532.3
Current Ratio 2.45
BMRN's Current Ratio is ranked lower than
70% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. BMRN: 2.45 )
Ranked among companies with meaningful Current Ratio only.
BMRN' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 6.11 Max: 17.58
Current: 2.45
1.22
17.58
Quick Ratio 1.84
BMRN's Quick Ratio is ranked lower than
74% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BMRN: 1.84 )
Ranked among companies with meaningful Quick Ratio only.
BMRN' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 5.22 Max: 17.58
Current: 1.84
1.18
17.58
Days Inventory 573.21
BMRN's Days Inventory is ranked lower than
97% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 120.79 vs. BMRN: 573.21 )
Ranked among companies with meaningful Days Inventory only.
BMRN' s Days Inventory Range Over the Past 10 Years
Min: 367.05  Med: 517.63 Max: 751.15
Current: 573.21
367.05
751.15
Days Sales Outstanding 67.60
BMRN's Days Sales Outstanding is ranked lower than
51% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. BMRN: 67.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.96  Med: 74.31 Max: 86.7
Current: 67.6
50.96
86.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.04
BMRN's Price/Tangible Book is ranked lower than
76% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. BMRN: 9.04 )
Ranked among companies with meaningful Price/Tangible Book only.
BMRN' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.85  Med: 7.29 Max: 21.92
Current: 9.04
3.85
21.92
Price/Projected FCF 100.12
BMRN's Price/Projected FCF is ranked lower than
97% of the 172 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. BMRN: 100.12 )
Ranked among companies with meaningful Price/Projected FCF only.
BMRN' s Price/Projected FCF Range Over the Past 10 Years
Min: 24.95  Med: 82.85 Max: 234.29
Current: 100.12
24.95
234.29
Price/Median PS Value 1.00
BMRN's Price/Median PS Value is ranked lower than
58% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BMRN: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
BMRN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.23 Max: 4.14
Current: 1
0.38
4.14
Earnings Yield (Greenblatt) (%) -1.03
BMRN's Earnings Yield (Greenblatt) (%) is ranked higher than
68% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. BMRN: -1.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMRN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.03  Med: 1.20 Max: 4
Current: -1.03
-1.03
4

More Statistics

Revenue(Mil) $891
EPS $ -1.11
Beta1.76
Short Percentage of Float5.32%
52-Week Range $62.12 - 151.75
Shares Outstanding(Mil)161.59

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 1,097 1,371 1,457
EPS($) -1.67 -0.76 0.52
EPS without NRI($) -1.67 -0.76 0.52

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 

More From Other Websites
BioMarin reports 1Q loss Apr 28 2016
BioMarin reports 1Q loss Apr 28 2016
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 28 2016
4:17 pm Biomarin Pharm reports Q1 (Mar) results, misses on revs; reaffirms FY16 revs guidance Apr 28 2016
BioMarin Announces First Quarter 2016 Financial Results Apr 28 2016
BioMarin Announces First Quarter 2016 Financial Results Apr 28 2016
Q1 2016 Biomarin Pharmaceutical Inc Earnings Release - After Market Close Apr 28 2016
Sanofi Presses Medivation to Hold Talks After $9.3B Offer Apr 28 2016
Should You Buy BioMarin Pharmaceutical (BMRN) Ahead of Earnings? Apr 27 2016
This Rare Children’s Disease Drug Is Pitting Patients Against the FDA Apr 26 2016
4 Biotechs That Will Escape Weak Seasonal Trends for the Sector Apr 26 2016
5 Biotech Stocks to Bet on This Earnings Season Apr 25 2016
BioMarin (BMRN) Q1 Earnings: Stock Likely to Beat Estimates Apr 25 2016
BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of... Apr 21 2016
BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of... Apr 21 2016
XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study Apr 21 2016
Sarepta: That Really Wasn't Good Apr 21 2016
Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals Apr 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK